Intellectual Property Workshop
Gianna J. Arnold is vice chair of the Life Sciences practice and a partner in the Intellectual Property & Technology Practice at Saul Ewing, LLP. She represents Fortune 500 corporations, start-up and growth companies, and universities in the development and management of patent, trademark and copyright portfolios, sponsored research, joint development, licensing and product development. Gianna regularly prepares opinions on matters including patentability, validity, infringement and freedom to use. Gianna counsels start-up and early stage companies in regard to the protection of their intellectual assets and prepares corresponding agreements. Prior to joining Saul Ewing, Gianna was a principal at Miles & Stockbridge, where her practice included patent, trademark, copyright, trade secret and unfair competition law in business, intellectual property, licensing and litigation matters relating to life sciences. She also has a scientific background that includes experience as an analytical chemist in the biochemical and environmental realms.
Linda Yaswen-Corkery, Ph.D. is the Business Development & Alliance Strategy Director responsible for developing internal and external partnerships for the Office of Research & Development at the University of Maryland, Baltimore. Dr. Yaswen-Corkery brings over 15 years of experience directing business and product development, as well as intellectual property strategy and management. Prior to joining the University of Maryland, Linda was the VP of Business Development and Chief Compliance Officer for a biotech start-up as it grew and became an SEC reporting entity. The biotech start-up grew from 4 employees to over 75; she launched domestic and international business development initiatives and established key business alliances that facilitated private-public collaboration and launched new product lines. Linda has a PhD in Immunology and Molecular Pathology from the University of Florida, Department of Medicine. She completed further research as an NIH postdoctoral fellow and staff fellow. Linda is a recognized facilitator and negotiator, and has represented business and technology interests to secure funding and investor support.
Adam Van Dyke, Ph.D. began his career in science with an strong interest in psychology and behavior. Eventually realizing that he was more interested in the inner workings of the brain rather than the clinical disorders, he decided to continue his training and obtain more wet-bench oriented research studying the effects of stroke on the brain. Combining the results from the field, the lab, as well as his own work, they theorized a novel idea for what is "required" for an antidepressant to have clinical efficacy. At the time, Adam was taking a Entrepreneurship in Life Science course run by Ken Malone and Martha Connolly who provided invaluable advice on how to protect our intellectual property and who they needed to talk to about monetizing their idea. After many conversations with those in the biotechnology space, Adam decided to start a company to develop their idea that started in the lab and bring it to the market. As a company, they have partnered with a medicinal chemist in the pharmacy school to synthesize novel chemicals that engage our target. They are also branching out into the technology sector in developing translational tools for the monitoring depressive symptoms and the effectiveness of other antidepressants. Adam received his BS in Behavioral Psychology, MS in Neuroscience and PhD in Neuroscience